Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: A three-year follow-up study

Chen, Chun; Qu, Zhiguo; Yin, Xiaoguang; Shang, Chunyu; Ao, Qiang; Gu, Yongquan; Liu, Ying

doi:10.3892/mmr.2016.5745

Cited by 59 publications

(41 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cai et al [ 35 ] evaluated the cotransplantation of autologous BMMSCs and allogeneic UCMSCs for treating ONFH and observed therapeutic effects without severe adverse effects at 12 months after transplantation. Chen et al [ 36 ] analyzed the clinical effects of transplanting allogeneic hUCMSCs for the treatment of ONFH and achieved clear results with no obvious side-effects after a three-year follow-up. However, there were only 30 cases and 9 cases in the studies of Cai et al and Chen et al, respectively.…”

Section: Outcomes In Clinical Applicationsmentioning

confidence: 99%

Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research

Lin

Liang

et al. 2018

Stem Cell Res Ther

View full text Add to dashboard Cite

Osteonecrosis of the femoral head (ONFH) is a refractory disease that is associated with collapse of the femoral head, with a risk of hip arthroplasty in younger populations. Thus, there has been an increased focus on early interventions for ONFH that aim to preserve the native articulation. Stem cell therapy is a promising treatment, and an increasing number of recent studies have focused on this topic. Many clinical studies have reported positive outcomes of stem cell therapy for the treatment of ONFH. To improve the therapeutic effects of this approach, many related basic research studies have also been performed. However, some issues must be further explored, such as the appropriate patient selection procedure, the optimal stem cell selection protocol, the ideal injection number, and the safety of stem cell therapy. The purpose of this review is to summarize the available clinical studies and basic research related to stem cell therapy for ONFH.

show abstract

Section: Outcomes In Clinical Applicationsmentioning

confidence: 99%

Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research

Lin

Liang

et al. 2018

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…Besides, they are able to replenish simultaneously the stem cell pool through self-renewal [ 1 ]. These features make them potential elements of cell-based therapies of the musculoskeletal system, for example, in case of osteoarthritis [ 2 , 3 ], osteonecrosis [ 4 ], or other bone and cartilage injuries. The isolation method of this cell type is well described; therefore, it is an everyday process to extract MSCs from bone marrow, and a similar cell population can be obtained from adipose tissue, umbilical cord blood, or skeletal muscle [ 5 – 8 ].…”

Section: Introductionmentioning

confidence: 99%

The Effects of Hyperacute Serum on the Elements of the Human Subchondral Bone Marrow Niche

Simon

Major²,

Vácz

et al. 2018

Stem Cells International

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are widely used in laboratory experiments as well as in human cell therapy. Their culture requires animal sera like fetal calf serum (FCS) as essential supplementation; however, animal sera pose a risk for clinical applications. Human blood derivatives, for example, platelet-rich plasma (PRP) releasates, are potential replacements of FCS; however, it is unclear which serum variant has the best effect on the given cell or tissue type. Additionally, blood derivatives are commonly used in musculoskeletal diseases like osteoarthritis (OA) or osteonecrosis as “proliferative agents” for the topical MSC pool. Hyperacute serum (HAS), a new serum derivative, has been designed to approximate the natural coagulation cascade with a single-step, additive-free preparation method. We investigated the effects of HAS on monolayer MSC cultures and in their natural niche, in 3D subchondral bone and marrow explants. Viability measurements, RT-qPCR evaluation for gene expression and flow cytometry for cell surface marker analysis were performed to compare the effects of FCS-, PRP-, or HAS-supplemented culture media. Monolayer MSCs showed significantly higher metabolic activity following 5 days' incubation in HAS, and osteoblast-specific mRNA expression was markedly increased, while cells also retained their MSC-specific cell surface markers. A similar effect was observed on bone and marrow explants, which was further confirmed with confocal microscopy analysis. Moreover, markedly higher bone marrow preservation was observed with histology in case of HAS supplementation compared to FCS. These findings indicate possible application of HAS in regenerative solutions of skeletal diseases like OA or osteonecrosis.

show abstract

“…As ONFH progresses, it can eventually result in femoral head collapse and degenerative changes to the hip joint if effective treatment is not implemented [3]. Various surgical procedures, including core decompression [4] and various types of osteotomies [5], have been used to maintain femoral head stability and to avoid unpredictable results in younger patients [6]; however, despite some progress, effective treatment for ONFH remains a challenge [7]. …”

Section: Introductionmentioning

confidence: 99%

Adenovirus-Mediated Expression of BMP-2 and BFGF in Bone Marrow Mesenchymal Stem Cells Combined with Demineralized Bone Matrix For Repair of Femoral Head Osteonecrosis in Beagle Dogs

Peng

Wang²

2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: This study investigated the effect of using adenovirus-mediated expression of bone morphogenetic protein 2 (Ad-BMP-2) and basic fibroblast growth factor (bFGF) in bone marrow mesenchymal stem cells (BMSCs) in combination with a demineralized bone matrix (DBM) to repair osteonecrosis of the femoral head (ONFH) in Beagle dogs. Methods: A total of 30 Beagle dogs were selected for the isolation of BMSCs, which were cultured and transfected with the recombinant adenovirus vector Ad-BMP2-bFGF-GFP (carrying BMP-2 and bFGF) or a control adenovirus plasmid (encoding green fluorescent protein (Ad-GFP)). The expression of the transfected BMP-2 and bFGF proteins was detected by Western blotting. After transfection, the BMSCs were induced to undergo osteoblastic differentiation. The DBM was prepared to construct a DBM/BMSC complex. Beagle models of canine femoral head defects and necrosis were established and divided into control, DBM, DBM/BMSC, vector Ad-BMP2-bFGF-GFP and Ad-GFP groups. The composite graft was then implanted, and new bone morphology was visualized via X-ray at 3, 6 and 12 weeks after the operation. Hematoxylin and eosin (HE) staining and Masson’s trichrome staining were used to identify new bone formation. Immunohistochemistry was performed to calculate the density of new blood vessels. The compressive and bending strength of the BMSCs was evaluated at 12 weeks after the operation. Results: BMSCs were successfully isolated. The protein expression of BMP-2 and bFGF was significantly higher in the Ad-BMP-2/bFGF group than the normal and Ad-GFP groups. Compared with the control group, at 12 weeks after the operation, the DBM, DBM/BMSC, vector Ad-BMP2-bFGF-GFP and Ad-GFP groups showed a larger area of new bone, higher X-ray scores, greater neovascularization density, and increased compressive and bending strength. The most significant modifications occurred in thevector Ad-BMP2-bFGF-GFP group. Conclusion: The results indicate that the use of Ad-BMP-2/bFGF-modified BMSCs in conjunction with DBM could successfully repair ONFH in a dog model by promoting bone formation and angiogenesis.

show abstract

Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: A three-year follow-up study

Cited by 59 publications

References 27 publications

Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research

Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research

The Effects of Hyperacute Serum on the Elements of the Human Subchondral Bone Marrow Niche

Adenovirus-Mediated Expression of BMP-2 and BFGF in Bone Marrow Mesenchymal Stem Cells Combined with Demineralized Bone Matrix For Repair of Femoral Head Osteonecrosis in Beagle Dogs

Contact Info

Product

Resources

About